Does sex or ethnicity impact anti-tumour necrosis factor agent use in rheumatoid arthritis?

被引：0
|
作者：
Dennison, Elaine M. [1 ]
Jameson, Karen A. [1 ]
Marks, Jonathan [2 ]
Watson, Kath [3 ]
Hyrich, Kimme [3 ,4 ]
Symmons, Deborah [3 ,4 ]
Cooper, Cyrus [5 ]
机构：
[1] Univ Hosp Trust Southampton, MRC Lifecourse Epidemiol Unit, Southampton, Hants, England
[2] Univ Hosp Trust Southampton, Rheumatol Res Unit, Southampton, Hants, England
[3] Univ Manchester, Sch Biol Sci, Arthrit Res UK Ctr Epidemiol, Div Musculoskeletal & Dermatol Sci, Manchester, Lancs, England
[4] Cent Manchester NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, NIHR Manchester Musculoskeletal Biomed Res Unit, Manchester, Lancs, England
[5] Univ Oxford, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, NIHR Musculoskeletal Biomed Res Unit, Oxford, England
来源：
RHEUMATOLOGY | 2017年 / 56卷 / 04期
关键词：
DISEASE;
D O I：
10.1093/rheumatology/kew466
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：663 / 665
页数：3
相关论文
共 50 条
  • [1] Impact of anti-tumour necrosis factor therapy on the weight of patients with rheumatoid arthritis
    Alcorn, Nicola
    Tierney, Ann
    Wu, Olivia
    Gilmour, Harper
    Madhok, Rajan
    ANNALS OF THE RHEUMATIC DISEASES, 2010, 69 (08) : 1571 - 1571
  • [2] The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis
    Askling, Johan
    Dixon, Will
    CURRENT OPINION IN RHEUMATOLOGY, 2008, 20 (02) : 138 - 144
  • [3] Anti-tumour necrosis factor therapy and B cells in rheumatoid arthritis
    Leandro, Maria J.
    ARTHRITIS RESEARCH & THERAPY, 2009, 11 (05)
  • [4] Anti-tumour necrosis factor a therapy in rheumatoid arthritis: an update on safety
    Hyrich, KL
    Silman, AJ
    Watson, KD
    Symmons, DPM
    ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 (12) : 1538 - 1543
  • [5] Anti-tumour necrosis factor therapy and B cells in rheumatoid arthritis
    Maria J Leandro
    Arthritis Research & Therapy, 11
  • [6] The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor
    Harrold, Leslie R.
    Reed, George W.
    Kremer, Joel M.
    Curtis, Jeffrey R.
    Solomon, Daniel H.
    Hochberg, Marc C.
    Greenberg, Jeffrey D.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 (02) : 430 - 436
  • [7] The impact of anti-tumour necrosis factor therapy for rheumatoid arthritis on the use of other drugs and hospital resources in a pragmatic setting
    Sandhu, R. S.
    Treharne, G. J.
    Douglas, K. M. J.
    Cassim, K.
    Saratzis, A.
    Piper, H.
    Erb, N.
    Jenkins, D.
    Tavakoli, M.
    Deighton, C.
    Kitas, G. D.
    MUSCULOSKELETAL CARE, 2006, 4 (04) : 204 - 222
  • [8] Retention of tocilizumab and anti-tumour necrosis factor drugs in the treatment of rheumatoid arthritis
    Hishitani, Y.
    Ogata, A.
    Shima, Y.
    Hirano, T.
    Ebina, K.
    Kunugiza, Y.
    Shi, K.
    Narazaki, M.
    Hagihara, K.
    Tomita, T.
    Yoshikawa, H.
    Tanaka, T.
    Kumanogoh, A.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2013, 42 (04) : 253 - 259
  • [9] Peptostreptococcal pericarditis complicating anti-tumour necrosis factor α treatment in rheumatoid arthritis
    Harney, S
    O'Shea, FD
    FitzGerald, O
    ANNALS OF THE RHEUMATIC DISEASES, 2002, 61 (07) : 653 - 654
  • [10] Neutropenia while receiving anti-tumour necrosis factor treatment for rheumatoid arthritis
    Rajakulendran, S.
    Gadsby, K.
    Allen, D.
    O'Reilly, S.
    Deighton, C.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 (12) : 1678 - 1679
12345